ARMP
ARMP clinical trials: Armata Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where Armata Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 13
- Trials linked
- 13
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ARMP on the catalyst calendar · ARMP registry changes
- Primary completion Nov 7, 2024ActualPhase 1/Phase 2NCT05184764Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus BacteremiaArmata Pharmaceuticals, Inc. · BacteremiaCompletedARMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 17, 2024ActualPhase 2NCT05616221Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and...Armata Pharmaceuticals, Inc. · Non-cystic Fibrosis BronchiectasisCompletedARMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2022ActualPhase 1/Phase 2NCT04596319Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and...Armata Pharmaceuticals, Inc. · Cystic FibrosisCompletedARMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 22, 2017ActualPhase 2NCT03196219A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult SubjectsArmata Pharmaceuticals, Inc. · Dental CariesCompletedARMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 5, 2017ActualPhase 2NCT03052842A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip ApplicationArmata Pharmaceuticals, Inc. · Dental CariesCompletedARMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 29, 2017ActualPhase 2NCT03004365A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental SubjectsArmata Pharmaceuticals, Inc. · Dental CariesCompletedARMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2016ActualPhase 2NCT02594254Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental SubjectsArmata Pharmaceuticals, Inc. · Dental CariesCompletedARMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2016ActualPhase 2NCT02509845Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental SubjectsArmata Pharmaceuticals, Inc. · Dental CariesCompletedARMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2015ActualPhase 2NCT02254993Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel DosesArmata Pharmaceuticals, Inc. · Dental CariesCompletedARMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2014ActualPhase 2NCT02044081Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy AdultsArmata Pharmaceuticals, Inc. · Dental CariesCompletedARMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT03395769Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage TherapeuticArmata Pharmaceuticals, Inc.No longer availableARMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT03395743Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage TherapeuticArmata Pharmaceuticals, Inc.No longer availableARMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2016ActualPhase 1NCT02757755Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy AdultsArmata Pharmaceuticals, Inc. · Healthy VolunteersCompletedARMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner